NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Tarsus Pharmaceuticals, Inc. (TARS) Stock Analysis

Tarsus Pharmaceuticals, Inc. (TARS) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TARS

$90.78

+$7.58 (+9.10%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TARS with… →

TARS Key Statistics

As of Sep 4, 2026
Trading
Open
$82.70
Previous Close
$83.21
Day's Range
81.07–91.53
52-Week Range
48.20–91.53
Volume
1.60M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.54
Valuation
Market Cap
$3.98B
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
39.05
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
6.57
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.07
Financials (FY)
Revenue (FY)
$451.36M+146.71%
Net Income (FY)
−$66.42M
Profit marginThe share of revenue left as profit after all costs and taxes.
−7.66%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
43.88M
1-Year Return
+58.07%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
975.84K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TARS Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+10.87%
2025+47.88%
2024+173.43%
2023+38.13%
2022−34.84%
2021−45.56%
2020 (partial year)+100.83%

As of September 4, 2026.

TARS Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$451.36M−$66.42M−14.7%
2024$182.95M−$115.55M−63.2%
2023$17.45M−$135.89M−778.9%
2022$25.82M−$62.09M−240.5%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$451.36M$420.68M−$70.97M−$66.42M−14.7%
2024$182.95M$170.13M−$120.57M−$115.55M−63.2%
2023$17.45M$15.85M−$143.16M−$135.89M−778.9%
2022$25.82M$24.86M−$62.71M−$62.09M−240.5%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TARS Valuation vs Biotechnology Median

Median of 656 stocks
MetricTARSBiotechnology medianvs median
P/S ratio6.5715.2657% below
Profit margin−7.66%0.00%7.7 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Tarsus Pharmaceuticals, Inc. (TARS) at $3.98B. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 370.

TARS last closed at $90.78 on September 4, 2026. That is +$7.58 (+9.10%) against the previous close. Over the past 52 weeks the price has ranged from $48.20 to $91.53. The latest close sits 88.34% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $451.36M. Against the prior fiscal year total of $182.95M, that is a change of +146.71%. The same year closed with a net loss of $66.42M. The reported profit margin is −7.67%. That is 7.7 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −1.07.

Across the 4 fiscal years on file, revenue moves from $25.82M in 2022 to $451.36M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. On forward earnings the ratio is 39.05. Measured against sales, the shares trade at 6.57 times revenue. On price-to-sales that is 56.96% below the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is +58.07%. Across 5 years the annualized return works out at +27.76%. Beta against the wider market is reported at 0.54. Annualized volatility over the trailing 5 years is 58.91%.

Growth & Income

No dividend is on file for TARS.

So far in 2026 the price is +10.87%. Across the complete calendar years on file, 2024 returned +173.43% and 2021 returned −45.56%. Of the 5 complete calendar years on file, 3 finished higher.

Peer Comparison

Tarsus Pharmaceuticals, Inc. (TARS) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tarsus Pharmaceuticals, Inc. TARS $3.98B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Tarsus Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Tarsus Pharmaceuticals, Inc.

Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States. The company offers XDEMVY, a lotilaner ophthalmic solution for the treatment of demodex blepharitis caused by the infestation of Demodex mites. It sells its products to specialty pharmacies and distributors, as well as clinics, hospitals, pharmacies, and federal healthcare programs. The company also develops TP-04, a sterile aqueous gel formulation of lotilaner in Phase 2 trial for the treatment of ocular rosacea; and TP-05, an oral tablet formulation of lotilaner in Phase 2 trial for the prevention of Lyme disease, as well as in pre-clinical studies for community malaria reduction. In addition, it is developing the lotilaner active pharmaceutical ingredient (API) to address diseases in human medicine, including eye care and infectious disease prevention. The company has a development and license agreement with Xi An Grand Chang An Pharmaceutical Co., Ltd. for the development and commercialization of TP-03 in China for the treatment of Demodex blepharitis and meibomian gland disease. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.

Visit website →